Insider · CIK 0001817160

Hansen Gwenn

Reports to the SEC for 1 company · BRISBANE, CA

sec.gov

Transactions

Companies

Filings

CIK

0001817160

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-10-15	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+1,452 sh	$1.86	+$2,700.72	118,679
2026-10-15	NRIXNurix Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−1,452 sh	$25.00	−$36.3K	117,227
2026-10-15	NRIXNurix Therapeutics, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−1,452 sh	—	—	59,406
2026-09-01	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+1,452 sh	$1.86	+$2,700.72	118,679
2026-09-01	NRIXNurix Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−1,452 sh	$25.47	−$37K	117,227
2026-09-01	NRIXNurix Therapeutics, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−1,452 sh	—	—	60,858
2026-08-05	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+4,356 sh	$1.86	+$8,102.16	121,583
2026-08-05	NRIXNurix Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−4,356 sh	$25.00	−$109K	117,227
2026-08-05	NRIXNurix Therapeutics, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−4,356 sh	—	—	62,310
2026-08-04	NRIXNurix Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−1,500 sh	$23.87	−$35.8K	119,838
2026-08-04	NRIXNurix Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−2,611 sh	$24.64	−$64.3K	117,227
2026-07-30	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+3,750 sh	—	—	118,755
2026-07-30	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+2,858 sh	—	—	121,613
2026-07-30	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+3,572 sh	—	—	125,185
2026-07-30	NRIXNurix Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−3,847 sh	$23.38	−$90K	121,338
2026-07-30	NRIXNurix Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−3,750 sh	—	—	11,250
2026-07-30	NRIXNurix Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−2,858 sh	—	—	20,009
2026-07-30	NRIXNurix Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−3,572 sh	—	—	39,303
2026-06-25	NRIXNurix Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−5,394 sh	$20.00	−$108K	115,005
2026-04-30	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+2,000 sh	—	—	117,005
2026-04-30	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+3,750 sh	—	—	120,755
2026-04-30	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+2,858 sh	—	—	123,613
2026-04-30	NRIXNurix Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−3,214 sh	$16.65	−$53.5K	120,399
2026-04-30	NRIXNurix Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−2,000 sh	—	—	0
2026-04-30	NRIXNurix Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−3,750 sh	—	—	15,000
2026-04-30	NRIXNurix Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−2,858 sh	—	—	22,867
2026-02-10	NRIXNurix Therapeutics, Inc. · Employee Stock Option (right to buy)A Award	Chief Scientific Officer	AAward	+93.8K sh	—	—	93,750
2026-02-10	NRIXNurix Therapeutics, Inc. · Restricted Stock UnitsA Award	Chief Scientific Officer	AAward	+42.9K sh	—	—	42,875
2026-02-03	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+31.3K sh	$0.84	+$26.3K	115,005
2026-02-03	NRIXNurix Therapeutics, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−31.3K sh	—	—	0
2026-01-30	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+3,207 sh	—	—	79,958
2026-01-30	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+2,000 sh	—	—	81,958
2026-01-30	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+3,750 sh	—	—	85,708
2026-01-30	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+2,859 sh	—	—	88,567
2026-01-30	NRIXNurix Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−4,797 sh	$16.58	−$79.5K	83,770
2026-01-30	NRIXNurix Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−98 sh	$17.37	−$1,702.427	83,672
2026-01-30	NRIXNurix Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−3,207 sh	—	—	0
2026-01-30	NRIXNurix Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−2,000 sh	—	—	2,000
2026-01-30	NRIXNurix Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−3,750 sh	—	—	18,750
2026-01-30	NRIXNurix Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−2,859 sh	—	—	25,725
2025-10-30	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+3,207 sh	—	—	72,230
2025-10-30	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+2,000 sh	—	—	74,230
2025-10-30	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+3,750 sh	—	—	77,980
2025-10-30	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+2,858 sh	—	—	80,838
2025-10-30	NRIXNurix Therapeutics, Inc.S Sale	Chief Scientific Officer	SSale	−4,087 sh	$12.80	−$52.3K	76,751
2025-10-30	NRIXNurix Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−3,207 sh	—	—	3,207
2025-10-30	NRIXNurix Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−2,000 sh	—	—	4,000
2025-10-30	NRIXNurix Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−3,750 sh	—	—	22,500
2025-10-30	NRIXNurix Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−2,858 sh	—	—	28,584
2025-10-14	NRIXNurix Therapeutics, Inc. · Restricted Stock UnitsA Award	Chief Scientific Officer	AAward	+20K sh	—	—	20,000

Recent filings

Accepted (ET)
Oct 154
Hansen Gwenn0001817160-26-000021
SEC(opens sec.gov)
Sep 14
Hansen Gwenn0001817160-26-000019
SEC(opens sec.gov)
Aug 54
Hansen Gwenn0001817160-26-000015
SEC(opens sec.gov)
Aug 54
Hansen Gwenn0001817160-26-000017
SEC(opens sec.gov)
Jul 304
Hansen Gwenn0001817160-26-000012
SEC(opens sec.gov)
Jun 254
Hansen Gwenn0001817160-26-000010
SEC(opens sec.gov)
Apr 304
Hansen Gwenn0001817160-26-000008
SEC(opens sec.gov)

Companies

Nurix Therapeutics, Inc.Chief Scientific OfficerNRIX

Address

C/O NURIX THERAPEUTICS, INC. 1600 SIERRA POINT PKWY

BRISBANE, CA, 94005